How much weight do people lose on Wegovy?

What the trial data can and cannot tell you about your own results

The 15% average weight loss seen in STEP 1 is a meaningful number, but averages hide a wide spread. A closer look at how much weight people have lost on Wegovy across the full trial programme shows some participants losing over 20%, while others lost closer to 5–8%. A newer, higher maintenance dose of 7.2 mg was approved by the MHRA in January 2026 and the dedicated single-dose pen followed in April 2026; trials reported average losses of around 20.7% over 72 weeks at that dose, narrowing the gap with tirzepatide results. The MHRA's announcement on the 7.2 mg pen sets out which patients it is licensed for.

If you are wondering how much weight you lose per week on Wegovy, the honest answer depends heavily on the dose level reached, how long treatment has been running, and individual factors including starting weight, diet, activity and how the body responds. Early weeks on the starting dose tend to show modest changes; the losses that trial participants are known for typically accumulate as the dose is titrated upward over several months. Expecting the full-trial average at week four sets an unrealistic benchmark. That is a question our prescribers hear regularly, and it is worth setting realistic expectations before you start.

None of this means the results are not real or worth pursuing. It means the right question is not "what will I lose?" but "is this medically appropriate for me, and what does a realistic plan look like?" That is what the consultation is for. Exploring the full range of outcomes gives a clearer picture than any single headline figure.

What UK private Wegovy treatment actually costs, and what some prices quietly leave out

UK private pricing for semaglutide varies between providers and by dose. Eli Lilly's September 2025 list-price increase for tirzepatide pushed the wider market's expectations upward, and Wegovy pricing has shifted accordingly. Broadly, private monthly costs have been reported in a range from roughly £149 to over £300 depending on dose and provider, though those figures are hedged because they move. A fuller breakdown of Wegovy pricing in the UK sets out what drives those differences.

The number that matters is not the headline figure on a website. Many quoted prices cover the medicine only. The consultation fee, the prescription charge, delivery, dose-review support and aftercare can all sit outside that number, added at checkout or bundled into a monthly subscription that auto-renews whether your circumstances have changed or not. Some services charge separately for each dose increase review. Others send the next pen automatically without any clinical re-assessment.

For anyone researching how much they might spend across a full year, the costs compound quickly when those extras are disaggregated. Annual cost estimates are worth reading before committing to a programme. The honest takeaway is that comparing monthly prices between providers is only useful if you are comparing the same scope of service, and that is rarely the case.

What nume charges, and why it is not the cheapest option

We do not compete on price. That is a deliberate position, not an oversight. One transparent price at nume covers the consultation, the prescription, the medicine, and free next-working-day tracked delivery by DPD. There are no hidden extras, no subscription you have to remember to cancel, and no pen dispatched without a prescriber re-reviewing your case first. Current treatment pricing is on the treatment page, where you can also start a free consultation.

If you compare us to the lowest-priced listing you can find, we will lose that comparison. We are fine with that. The question is what the lower price is built on. A prescription-only medicine that has been reviewed by a named clinician, dispensed from a GPhC-registered pharmacy (registration 9012878), and delivered tracked is a different product from a pen that arrives in an envelope from a seller whose clinical process you cannot verify. Our clinical model is built around genuine oversight at every stage, including every repeat.

Why price is the wrong yardstick for a prescription medicine

Wegovy requires a prescription for good reason. GLP-1 medicines have a well-characterised side-effect profile, interact with oral contraceptives in ways that matter clinically, and are contraindicated in certain conditions that a prescriber needs to screen for. The MHRA has explicitly warned that fake pens have been seized in large quantities from online sellers operating without the clinical safeguards that make these medicines safe. Reporting concerns about suspect sellers is possible via the Yellow Card scheme.

A service that prices aggressively may be cutting corners on the parts of the process that protect you, not on the parts that are genuinely discretionary. That is not a speculative concern. It is the pattern the MHRA's enforcement actions have consistently found. The right metric for choosing a provider is not the monthly cost; it is whether a real clinician reviews your case, whether the pharmacy is verifiable on the GPhC register, and whether the supply chain is the licensed UK one. If you want a clearer sense of how much weight people are losing on Wegovy right now, including figures from recent real-world use alongside the trial data, that context is worth reviewing before you decide.

If you are ready to have that conversation, checking your eligibility takes a few minutes and costs nothing. A prescriber, not software, reads your answers, usually the same day you submit.